These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24347322)

  • 1. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice.
    Lopes C; Ribeiro M; Duarte AI; Humbert S; Saudou F; Pereira de Almeida L; Hayden M; Rego AC
    Mol Neurobiol; 2014 Jun; 49(3):1126-42. PubMed ID: 24347322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
    Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
    Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.
    Ribeiro M; Rosenstock TR; Oliveira AM; Oliveira CR; Rego AC
    Free Radic Biol Med; 2014 Sep; 74():129-44. PubMed ID: 24992836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.
    Naia L; Ferreira IL; Cunha-Oliveira T; Duarte AI; Ribeiro M; Rosenstock TR; Laço MN; Ribeiro MJ; Oliveira CR; Saudou F; Humbert S; Rego AC
    Mol Neurobiol; 2015 Feb; 51(1):331-48. PubMed ID: 24841383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manganese Acts upon Insulin/IGF Receptors to Phosphorylate AKT and Increase Glucose Uptake in Huntington's Disease Cells.
    Bryan MR; Nordham KD; Rose DIR; O'Brien MT; Joshi P; Foshage AM; Gonçalves FM; Nitin R; Uhouse MA; Aschner M; Bowman AB
    Mol Neurobiol; 2020 Mar; 57(3):1570-1593. PubMed ID: 31797328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
    Ransome MI; Hannan AJ
    Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in Early-Symptomatic YAC128 Huntington's Disease Mice.
    da Fonsêca VS; da Silva Colla AR; de Paula Nascimento-Castro C; Plácido E; Rosa JM; Farina M; Gil-Mohapel J; Rodrigues ALS; Brocardo PS
    Mol Neurobiol; 2018 Sep; 55(9):7201-7215. PubMed ID: 29388082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
    Gil-Mohapel JM
    CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compromised IGF signaling causes caspase-6 activation in Huntington disease.
    Skotte NH; Pouladi MA; Ehrnhoefer DE; Huynh K; Qiu X; Nielsen SMB; Nielsen TT; Nørremølle A; Hayden MR
    Exp Neurol; 2020 Oct; 332():113396. PubMed ID: 32622701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
    Xie Y; Hayden MR; Xu B
    J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered microRNA regulation in Huntington's disease models.
    Lee ST; Chu K; Im WS; Yoon HJ; Im JY; Park JE; Park KH; Jung KH; Lee SK; Kim M; Roh JK
    Exp Neurol; 2011 Jan; 227(1):172-9. PubMed ID: 21035445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
    Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
    J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
    Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
    Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
    Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
    Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.